Biosolution Co.,Ltd.

086820.KQ - KOSDAQ

Bio Solution Co.,Ltd. develops, manufactures, and sells cell therapy products worldwide. The company offers CartiLife, an autologous chondrocyte cell-based therapy for the restoration of symptomatic and structural complications caused by articular cartilage defects; KeraHeal-Allo, a thermosensitive hydrogel-type allogenic keratinocyte cell-therapy product to promote re-epithelialization of deep 2nd-degree burn wounds; and KeraHeal, an autologous spray-type keratinocyte cell-based therapy for skin wounds. It also provides reconstructed human micro-tissue models comprising KeraSkin, an epidermis model; KeraSkin-FT, a full-thickness skin model; KeraSkin-M, a pigmented skin model; corneal models; SoluAirway, a airway mucosa model; SoluOral, an oral mucosa model; SoluDPNeuron, a dopaminergic neuron model; SoluDANeuron, an islet model; and SoluLiver, a liver model. In addition, the company provides human-derived primary cell cultures and primary cells for in vitro research; bio advanced materials; and cosmetics raw materials. The company was formerly known as MCTT Bio Co., Ltd. and changed its name to Bio Solution Co.,Ltd. in January 2016. Bio Solution Co.,Ltd. was founded in 2000 and is headquartered in Seoul, South Korea.

Biosolution Co.,Ltd. trades as 086820.KQ on KOSDAQ. Its latest stored price is $6,860.00 as of June 9, 2026.

Data updated June 9, 2026

Financial Snapshot